Alex Morozov was named the first chief medical officer of Pi Health, an oncology clinical trial and research technology company.
Morozov has overseen hundreds of oncology trials at companies including Pfizer, Bristol Myers Squibb, and Exelixis, where he contributed to the global approvals of multiple therapies such as Bavencio, Lorbrena, Opdivo/Yervoy, and Cabometyx.
The addition of Morozov follows Pi Health’s recent $30 million Series A financing and the launch of its cancer hospital in Hyderabad, India. The hospital serves as a model for integrating research and care delivery powered by the company’s proprietary end-to-end technology platform. With a network of health system partnerships spanning the U.S., Brazil, Australia, and India, Pi Health aims to accelerate the development of practice-changing therapies while democratizing access to clinical trials globally, the company said.
Before joining Pi Health, Morozov served as SVP and head of clinical development and clinical pharmacology at Exelixis, overseeing a portfolio spanning first-in-human and late-phase programs in oncology. At BMS, he led the clinical team overseeing the Opdivo-Yervoy portfolio, spearheaded several clinical trial innovation pilots, and built the first digital health team at BMS, overseeing a portfolio of digital programs across therapeutic areas leveraging technologies like remote monitoring, digital biomarkers, and AI/ML.
Morozov’s expertise spans early- and late-phase trials, clinical pharmacology, digital innovation, process optimization, and global execution.
“I am excited to join Pi Health in its mission to integrate clinical research and clinical practice on a global scale,” Morozov said in a statement. “Pi Health’s collaborations with health systems and commitment to diversity represents a paradigm shift in how we develop and access life-saving treatments. I look forward to partnering with our investigators, academic institutions, and biopharma drug developers to leverage our end-to-end platform and generative AI to improve speed, quality, and efficiency of drug development.”
